Ribavirin monotherapy increases sustained response rate in relapsers of end treatment virologic responders

Cho-Li Yen, Jia-Jang Chang, Tsung-Shih Lee, Ching-Jung Liu, Li-Wei Chen, Liang-Che Chang

INTRODUCTION

Interferon-α monotherapy for chronic hepatitis C virus (HCV) infection has been disappointing with a sustained response rate of only 20-25% after 24-48 wk of treatment[1,2]. Combination therapy with interferon-α and ribavirin has increased the sustained response rate to about 40-45%. With the advent of pegylated interferon-α, the sustained response rate of pegylated interferon-α plus ribavirin combination therapy was further advanced to 54-56%[3,4].

In spite of these recent advances, patients with HCV genotype 1 infection have lower response rates to interferon-α related therapy than patients infected with HCV genotypes 2 and 3[5,6]. Patients with HCV genotype 1b are recommended to receive 48 wk of interferon-α related combination treatments[5,6], which often include the pegylated interferon-α as a part of the treatment regimen. The side effect of pegylated interferon-α was reported to be similar[5] or milder than interferon-α[6], but the cost is much higher.

Ribavirin monotherapy has been unsuccessful in treating patients with chronic hepatitis C infection[7-9]. Ribavirin as an inhibitor of HCV viral replication, its mechanism of action in mono- or combination therapy of chronic hepatitis C remains unclear.

This study is designed to assess the efficacy of ribavirin monotherapy in treating chronic hepatitis C infected patients with low viral load after interferon-α plus ribavirin combination therapy, in the hope of reducing the medical cost and undesirable side effects due to resumption of interferon-related therapy.

MATERIALS AND METHODS

Materials

This study was conducted from March 1999 to July 2003. Sixty-five patients were recruited for the investigation. Eligible patients were previously untreated chronic C hepatitis patients with elevation of alanine transaminase (ALT) level 2-10 times over the normal upper limit for more than

© 2005 The WJG Press and Elsevier Inc. All rights reserved.
six months. Patients were excluded if they had decompensated liver cirrhosis, alcoholism, hepatitis B virus superinfection, uncontrolled diabetes mellitus, autoimmune disorders, human immunodeficiency virus infection, uremia, or organ transplantation. Liver biopsies were done before and after the combination therapy and were read and given a Knodell histologic activity index (HAI) numeric score[14] by the same pathologist. Patients, who needed ribavirin dosage reduction, were excluded from the study.

**Methods**

Patients who fulfilled the above criteria were given combination therapy consisting of 3 million U alpha-2a interferon three times per week administered subcutaneously or intramuscularly plus ribavirin 1 000 or 1 200 mg/d based on the body weight (1 000 mg if body weight < 70 kg, 1 200 mg if body weight ≥ 70 kg). Liver function test and hemogram were performed monthly during the treatment. After the combination treatment, the liver function test was followed up monthly over the first 3 mo then bimonthly in all groups. The HCV-RNA level was measured again when the liver function test became abnormal during the follow-up period after the combination therapy.

Non-responder is defined as detection of HCV-RNA level at the end of 24 wk of combination therapy. End treatment biochemical response is defined as normalization of liver function test at the end of combination treatment with or without detectable HCV-RNA. End treatment virologic response is defined as normalization of liver function test and undetectable HCV-RNA (<100 copies/mL) at the cessation of combination treatment. Sustained virologic response is defined as normalization of ALT and undetectable HCV-RNA level (<100 copies/mL) at the cessation of the combination therapy and over the following 12 mo. Biochemical relapse is defined as elevation of ALT ≥ 1.5× normal upper limit after combination therapy with or without detectable HCV-RNA within 6 mo after end treatment biochemical response.

Patients who experienced biochemical relapse within 6 mo after combination therapy, according to their intention and consent to be treated, received 24 wk of ribavirin monotherapy, and in dosages described above. Patients diagnosed as having diabetes mellitus, fatty liver, other viral infections, and other possible causes of abnormal liver function test were excluded. During ribavirin monotherapy, liver function test was followed up monthly over the first 3 mo, then bimonthly until the end of one year. HCV-RNA level was re-checked at the beginning of monotherapy, at 12 wk into the therapy and at the end of the monotherapy.

**Virologic method**

Quantification of HCV-RNA was first performed with a reverse transcription-polymerase chain reaction and a digoxigenin detection system[9]. The titer of HCV-RNA was expressed in million genome equivalent (Meq) per milliliter. The lower limit of detection of the test is 0.01 Meq/mL. For HCV-RNA titers less than 0.01 Meq, the specimens were reexamined using Amplicor qualitative HCV-RNA assay (Roche Diagnostics, Branchburg, NJ), which has a lower limit of sensitivity of 100 copies/mL. Bayer Versant 3.0 (bDNA) Quantitative Assay (Bayer Diagnostics, Emeryville, CA) was used to examine HCV-RNA levels between 100 and 10 000 copies/mL, the lowest level of detection is 3 200 copies/mL. The genotyping of HCV was carried out using reverse hybridization assay (Inno-LiPA HCV-II; Innogenetics, Gent, Belgium).

**Statistical analysis**

Baseline data of quantitative variables were expressed as mean±SD. Pair data of post-treatment response in groups were compared with t test, F test or χ² test. P values <0.05 were considered statistically significant.

**RESULTS**

Three of 65 patients failed to complete the study, including two patients who were unable to tolerate the side effect of interferon-α and one patient who experienced severe insomnia and dyspnea caused by ribavirin. Among 62 patients who completed the study, 26 (41.9%) were non-responders. The remaining 36 patients (58.1%) achieved end treatment virologic response. Fifty patients (80%) including 16 non-responders and 34 of 36 end treatment virologic responders (ETVRs) achieved end treatment biochemical response. The HCV-RNA levels in 12 of 16 non-responders who achieved end treatment biochemical response were ≤ 0.2 Meq/mL as ALT relapsed. They were included in the monotherapy. Two among 36 ETVRs demonstrated persistent abnormal liver function test resulting from fatty liver as HCV-RNA levels were undetectable (<100 copies/mL) in four consecutive follow-up tests for one year and obvious fatty liver was demonstrated by ultrasonography. They were excluded from the monotherapy. Mild and transient elevations of ALT levels (<1.5 normal upper limit), which returned to normal one month later, were observed in four ETVRs at the fifth month after combination therapy. They were also excluded from the monotherapy. In total, 12 of 36 ETVRs demonstrated biochemical relapse within 5 mo after combination therapy including eight patients with HCV-RNA reappearance and four patients without detectable serum HCV-RNA levels (HCV-RN<100 copies/mL). Four of HCV-RNA reappearing ETVRs and all four RNA-negative ETVRs were included in the study. In total, ribavirin monotherapy was administered to 20 biochemical relapers including four of eight HCV-RNA reappearing ETVRs, four HCV-RNA negative ETVRs, and 12 HCV-RNA levels ≤ 0.2 Meq/mL non-responders. The baseline characteristics and virologic profiles of these 62 patients are divided into three groups according to treatment responses as presented in Table 1. No significant difference is seen in gender, age, HCV genotype, cirrhosis, patient number of HCV-RNA >2 Meq/mL, and HAI scores in pairwise comparisons among three treatment groups.

The initial HCV-RNA levels of 12 non-responders who were eligible for monotherapy ranged from 0.0046 to 0.2 Meq/mL at biochemical relapse. Three patients failed to normalize the liver function tests. Nine patients (75%) experienced normalization of ALT during the monotherapy. One of these nine patients achieved sustained virologic
response when the monotherapy ended. The HCV-RNA level was 0.011 Meq/mL at the start of the monotherapy. This patient sustained the virologic response one year after monotherapy. Two of these nine patients, although HCV-RNA levels were 0.0046 and 0.08 Meq/mL, respectively at the beginning of the monotherapy, experienced 2 and 3 years of biochemical remission after the monotherapy. The HCV-RNA levels were 2.6 and 0.868 Meq/mL, respectively at the end of follow-up. The ALT levels of the remaining six patients became abnormal again and the HCV-RNA levels remained detectable at the end of the monotherapy.

In four HCV-RNA negative biochemical relapers of ETVRs, the ALT levels normalized and the HCV-RNA levels remained undetectable for 2 years after monotherapy. In two of four HCV-RNA reappearing biochemical relapers of ETVRs, ribavirin monotherapy was given at 1 and 3 mo after the detection of ALT elevation. The HCV-RNA levels in both patients became undetectable (<100 copies/mL) again at the end of the monotherapy and remained undetectable for over one year. The HCV-RNA levels were 3.8 and 0.061 Meq/mL, respectively at the start of monotherapy. The remaining two of four HCV-RNA reappearing biochemical relapers of ETVRs received ribavirin monotherapy as late as 6 mo after the cessation of combination treatment and failed to respond to ribavirin monotherapy. The HCV-RNA levels were 1.06 and 2.7 Meq/mL, respectively at the beginning of monotherapy, and remained detectable at the end of monotherapy.

The demography of patients who had sustained virologic response after monotherapy is shown in Table 2. With seven additional sustained virologic responders after the monotherapy, the number of patients with sustained virologic response increased from 24 to 31 (50% of 62 enrolled patients) at the conclusion of the study.

**DISCUSSION**

In the present study, we have shown that adjuvant ribavirin monotherapy given early at the signs of recurrent liver function abnormalities following the completion of interferon-ribavirin combination therapy achieved sustained virologic response in seven of 20 patients. These results contrast with previous studies wherein ribavirin monotherapy, used at the start of the anti-viral treatment or administered in non-responders when the viral loads were well established, showed little efficacy. Our results further contrast with a previous randomized controlled study by Shiffman et al., wherein no enhanced anti-viral response was observed in virologic responders of combination therapy who continued ribavirin monotherapy.

We think that different clinical outcome in our study may be attributable to the following. First, the patients studied here are treatment-naïve, unlike Shiffman's study in which the patients were relapers after interferon monotherapy. Second, we employed ribavirin in a different treatment strategy-under the condition when the viral loads of the patients were low and soon after the combination therapy. The ribavirin monotherapy in our study was administered 1 to 3 mo after liver function abnormalities instead of continuing immediately after the combination or interferon therapy as carried out by Shiffman et al.

Mathematical analyses of viral load changes have provided critical insight into the pathogenesis of the chronic viral infection of HCV. Dose-dependent exponential decline in viral load has been demonstrated by Lam et al. in interferon treatment as well as Buti et al. in pegylated interferon treatment. The decline is slower in patients infected by HCV genotype 1 and in African Americans. After the rapid clearing of the viral RNA in the first phase, viral decline slows and becomes variable in the second phase. The effect of the first phase is believed to be predominantly due to the inhibition of de novo infection of susceptible cells by interferon. The second phase of viral decline is thought to depend on the clearing of the virus from the infected cells with or without cell turnover. To explain our results, we hypothesize that the significant reduction in viral load after the initial interferon-based monotherapy or combination therapy may have created a genetic bottleneck wherein only attenuated HCV variants escaped and persisted. When reemerged, these attenuated HCV variants may have provided a boost to the immune system that was accompanied by liver function abnormalities. Indeed,
a previous report by Balladini et al\cite{23} showed that serum ALT level is correlated with the number of lobular CD8+ cells and histologic manifestation. ALT elevation, in our cases, may coincide with a rebound of immune response to the reemergence of virus. The timely administration of ribavirin at this point may have reduced the viral load and/or impaired the virus further by introducing mutations into the viral genome. These conditions may have mimicked a booster effect in vaccination procedure and thus favor the induction of an effective host immune response against residual HCV, leading to the eventual viral clearance. This would explain why continuous ribavirin monotherapy is ineffective, while restarting ribavirin monotherapy at the signs of reemergence of viral RNA and/or liver function abnormalities as described here shows significant efficacy. Continuing ribavirin immediately after the interferon therapy may reduce HCV replication, but at the same time eliminate the immunological booster effect provided by the reemergence of low-level replication of “attenuated” HCV.

The mechanisms of action of ribavirin in the treatment of HCV infection remain incompletely understood. Ribavirin monotherapy has been shown previously to induce transient improvement of liver function test in chronic HCV-infected individuals, but had no sustained response\cite{10-12,23}. While the added benefit of ribavirin to interferon treatment is obvious, the mechanism of its action is unclear, as it did not show significant inhibition of viral production\cite{24}. Ribavirin has been shown to decrease HCV replicon RNA sequence moderately and can cause a significant reduction in viral infectivity in a single round of poliovirus infection by increasing the viral mutation rate\cite{25,26}. Ribavirin has also been shown to enhance antiviral Th1 and suppress Th2 cytokines expression in human T cells\cite{27}. Further studies to clarify the role of ribavirin in improving the efficacy of our treatment protocol are needed.

In agreement with the previous report where 5% of the patients with sustained virologic response had persistent rise of ALT\cite{23}, two of 36 ETVRs (5%) in this study were found to have fatty liver and persistently abnormal ALT. Critical to the significance of this study is the inclusion of those four biochemical relapers who showed elevated ALT levels (>1.5-2.0× normal upper limit) but were serum HCV RNA-negative at the start of the ribavirin monotherapy. These four patients were able to normalize their ALT levels after the monotherapy. We think the conditions of these four patients would have worsened if had they been left untreated. Their hepatic abnormalities are clear indications of viral reemergence despite negative serum HCV levels. Indeed, a recent report using quantitative hepatic HCV-RNA measurement found that intrahepatic HCV RNA was detectable in 2% of sustained virologic responders, among them, two of five patients had reappearance of HCV-RNA\cite{23}. Two of four patients whose HCV-RNA occurred after end treatment virologic response responded to monotherapy is most intriguing in this study because monotherapy was minimally effective in non-responders. The observation requires a control and larger number of patients to clarify its role.

In conclusion, combination treatment with 24 wk of interferon and ribavirin achieved 40% of sustained virologic response in the previous study in this island\cite{23}. In the present study, we show that the sustained virologic response rate can be increased up to 50% by adjuvant ribavirin monotherapy following the combination therapy upon recurrence of ALT abnormalities. The present result further indicates 24 wk of interferon and ribavirin combination treatment followed by adjuvant ribavirin monotherapy when signs of HCV-RNA and ALT abnormalities appear can achieve nearly the same treatment goal as 48 wk of combination treatment especially in biochemical relapers of ETVRs before or on HCV-RNA reappearing, thus reducing the suffering associated with the latter treatment.

**ACKNOWLEDGEMENTS**

The authors wish to thank Miss T.P. Lu for her excellent preparation of blood samples and Mr. Wei-Chue Shyu for quantification of HCV-RNA and Miss Ya-Hui Shih for the preparation of the manuscript.

**REFERENCES**

1. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. *Hepatology* 1996; 24: 778–789
2. Balart LA, Perrillo R, Roddenderry J, Regensten F, Shim KS, Shieh YS, Taylor B, Dash S, Gerber MA. Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment. *Gastroenterology* 1993; 104: 1472–1477
3. Lai MY, Kao JH, Yang PM, Wang JT, Chen Pj, Chan KW, Chu JS, Chen DS. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. *Gastroenterology* 1996; 111: 1307–1312
4. Reichard O, Norkrans G, Fryden A, Bronnich JH, Sonnberger A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. *The Swedish Study Group. Lancet* 1998; 351: 83–87
5. Manns MP, McHutchison JG, Gordon SC, Rustogi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; 358: 958–963
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonzales FL, Haussinger D, Diago M, Carosi G, Dumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975–982
7. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. *Hepatology* 1997; 26: 1225–1275
8. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *Hepatitis Interventional Therapy Group. N Engl J Med* 1998; 339: 1485–1492
9. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. *International Hepatitis Interventional Therapy Group (IHT) Lancet* 1998; 352: 1426–1432
10. Di Bisceglie AM, Conjevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 1995; 123: 897–903
Shiffman ML, Hoofnagle JH, Ho DD, Yeh CT, Neumann AU, Nowak MA, Reddy KR, Buti M, Yen CL. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591–598

Hoofnagle JH, Ghany MG, Kleiner DE, Doo E, Heller T, Promrat K, Ong J, Khokhar F, Soza A, Herion D, Park Y, Everhart JE, Liang TJ. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003; 38: 66–74

Shiffman ML, Hofmann CM, Sterling RK, Luketic VA, Contos MJ, Sanayal AJ. A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response. J Infect Dis 2001; 184: 405–409

Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435

Yeh CT, Shyu WC, Sheen IS, Chu CM, Liaw YF. Quantitative assessment of hepatitis C virus RNA by polymerase chain reaction and a digoxigenin detection system: comparison with branched DNA assay. J Virol Methods 1997; 65: 219–226

Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123–126

Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398–4402

Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28–35

Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35: 930–936

Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787–793

Neumann AU, Layden TJ, Reddy KR, Levi-Drummer R, Poulakos J. The 2nd phase slope of HCV decline is highly predictive of sustained virologic response (SVR) following consensus interferon (infergen) treatment for chronic hepatitis C and is determined by genotype but not by dose [Abstract]. Hepatology 2000; 32: 356A

Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden T, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103–107

Ballardini G, Groff P, Pontisso P, Giastra F, Francesconi R, Lenzi M, Zauli D, Alberti A, Bianchi FB. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J Clin Invest 1995; 95: 2067–2075

Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245–252

Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6: 1375–1379

Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001; 98: 6895–6900

Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 1999; 30: 376–382

McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, Ling MH, Garaud JJ, Albrecht JK, Patel K, Dienstag JL, Morgan T. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002; 35: 688–693

Blatt LM, Tong MJ, McHutchison JG, Russell J, Schmid P, Conrad A. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers. J Interferon Cytokine Res 1998; 18: 75–80

Science Editor Li WZ Language Editor Elsevier HK